Over $20 Million Carved Out From Statistical, Operations enters 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI: NCTN Makes “Amazing Trials” Possible

“It is important to note that the $151 million does not capture the many other functions that NCI provides in support of the NCTN and the entire clinical trials enterprise,” Garrett said. “A few of these key centralized functions include the Cancer Trials Support Unit (CTSU), a ‘one-stop shop’ for the groups to access all trials, a Central Institutional Review Board (CIRB) to eliminate the need for local IRB approvals, tumor banking for each group, and ancillary studies funded to support biomarker and quality of life research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology. 
Silverstein during his surgical oncology fellowship, c. 1972This month on the Cancer History Project Podcast, Melvin J. Silverstein, Medical Director of Hoag Breast Center and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery at USC, sat down with Stacy Wentworth, radiation oncologist and medical historian, to reflect on his career—and founding the first free-standing breast center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login